Esperion Therapeutics Inc (NASDAQ:ESPR) had its target price lifted by equities research analysts at Needham & Company LLC to $58.00 in a report released on Monday. Needham & Company LLC’s target price points to a potential upside of 145.04% from the company’s previous close.
Other equities research analysts have also issued research reports about the company. Citigroup Inc set a $39.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 13th. Royal Bank of Canada set a $20.00 price objective on Esperion Therapeutics and gave the stock a “hold” rating in a research report on Tuesday, February 7th. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 2nd. Finally, Credit Suisse Group AG upgraded Esperion Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $28.24.
Esperion Therapeutics (NASDAQ:ESPR) traded up 25.575% on Monday, hitting $37.233. 26,206,462 shares of the company were exchanged. The stock’s market capitalization is $839.79 million. Esperion Therapeutics has a 52-week low of $9.40 and a 52-week high of $37.58. The stock’s 50-day moving average price is $23.80 and its 200-day moving average price is $15.00.
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Wednesday, February 22nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.24) by $0.05. During the same period last year, the firm posted ($0.58) earnings per share. On average, equities research analysts anticipate that Esperion Therapeutics will post ($6.04) earnings per share for the current fiscal year.
Your IP Address:
Several hedge funds and other institutional investors have recently made changes to their positions in ESPR. Keybank National Association OH acquired a new position in shares of Esperion Therapeutics during the fourth quarter valued at $159,000. Elkfork Partners LLC acquired a new position in shares of Esperion Therapeutics during the fourth quarter valued at $169,000. Advisor Group Inc. increased its position in shares of Esperion Therapeutics by 0.6% in the third quarter. Advisor Group Inc. now owns 14,437 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 85 shares during the last quarter. Virginia Retirement Systems ET AL acquired a new position in shares of Esperion Therapeutics during the third quarter valued at $242,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Esperion Therapeutics by 54.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 40,220 shares of the biopharmaceutical company’s stock valued at $504,000 after buying an additional 14,257 shares during the last quarter. 64.65% of the stock is owned by institutional investors and hedge funds.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.